$ENZC Enzolytics, Inc. Announces the Engagement of
Post# of 1003
(Total Views: 159)
Posted On: 05/11/2021 12:50:20 PM
$ENZC Enzolytics, Inc. Announces the Engagement of Ten Associates LLC As The Company's Strategic Communication Firm
https://www.accesswire.com/646448/enzolytics-...ation-firm
COLLEGE STATION, TX / ACCESSWIRE / May 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"
today announced it has engaged TEN Associates LLC (the "Consultant" to assist the Company in disseminating and updating meaningful, relevant and factual information about Enzolytics, and its progress in fulfilling its business strategy, to market makers, the brokerage community, individual investors, the media and the public.
Since the combination with BioClonetics Immunotherapeutics, Inc. in December of 2020, a little over five months ago, the Company has announced the achievement of and future plans for a series of significant milestones. The management team has concentrated on meeting or beating each of these milestones and furthering its advancement in developing new, patentable therapeutics and completing testing and clinical trials for its ITV-1 compound. Our focus and dedication to our technologies has resulting in our having limited time for providing detailed responses and information to shareholder questions as well as those from the investing public. The Company has purposely prioritized its science and the furtherance of its technologies to build shareholder value. However, by the addition of experienced investor relations personnel to our team, we hope to be able to share more information about our progress while continuing to focus on and furthering our significant therapeutic platforms. We will continue to provide timely Press Releases detailing our developments and will supplement such information on our Website.
We believe this will ensure the public market has accurate up-to-date information on the multiple fronts the Company has embarked while correcting the effects of disinformation. We see this as an important aspect of protecting shareholder value.
"We have shared with our investors and the public the many advancements, partnering prospects and new patentable developments over the past five months and have many more new developments that we will be outlining in the near future. As a result, we are confident in our future. We hope our plans for communicating the current and expected future progress toward success will be just as successful as our expected success in the lab," stated Charles Cotropia, CEO.
https://www.accesswire.com/646448/enzolytics-...ation-firm
COLLEGE STATION, TX / ACCESSWIRE / May 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"
today announced it has engaged TEN Associates LLC (the "Consultant" to assist the Company in disseminating and updating meaningful, relevant and factual information about Enzolytics, and its progress in fulfilling its business strategy, to market makers, the brokerage community, individual investors, the media and the public. Since the combination with BioClonetics Immunotherapeutics, Inc. in December of 2020, a little over five months ago, the Company has announced the achievement of and future plans for a series of significant milestones. The management team has concentrated on meeting or beating each of these milestones and furthering its advancement in developing new, patentable therapeutics and completing testing and clinical trials for its ITV-1 compound. Our focus and dedication to our technologies has resulting in our having limited time for providing detailed responses and information to shareholder questions as well as those from the investing public. The Company has purposely prioritized its science and the furtherance of its technologies to build shareholder value. However, by the addition of experienced investor relations personnel to our team, we hope to be able to share more information about our progress while continuing to focus on and furthering our significant therapeutic platforms. We will continue to provide timely Press Releases detailing our developments and will supplement such information on our Website.
We believe this will ensure the public market has accurate up-to-date information on the multiple fronts the Company has embarked while correcting the effects of disinformation. We see this as an important aspect of protecting shareholder value.
"We have shared with our investors and the public the many advancements, partnering prospects and new patentable developments over the past five months and have many more new developments that we will be outlining in the near future. As a result, we are confident in our future. We hope our plans for communicating the current and expected future progress toward success will be just as successful as our expected success in the lab," stated Charles Cotropia, CEO.
(0)
(0)